Introduction: The First Effective Antiviral

  • Herbert E. Kaufman


During the 1950s there was an explosion of research on antivirals by a number of superb scientists with excellent resources. However, the lack of progress in discovering a clinically useful agent led to widespread discouragement. In fact, the company to which I brought idoxuridine—the first clinically effective antiviral—had closed its antiviral research section a week before my arrival. At that time, to my knowledge, no pharmaceutical company was engaged in antiviral research.


Herpes Simplex Thymidine Kinase Oral Acyclovir Herpetic Keratitis Herpes Simplex Keratitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brown F, Planterose DN, Stewart DL (1961): Effect of p-fluorophenylalanine on the multiplication of foot and mouth disease virus. Nature (London) 191:414–415.CrossRefGoogle Scholar
  2. Burns RP (1963): A double-blind study of IDU in human herpes simplex keratitis. Arch Ophthalmol 70:381–384.CrossRefGoogle Scholar
  3. Calabresi P (1963): Current status of clinical investigations with 6-azauridine, 5-iodo-2′-deoxyuridine and related derivatives. Cancer Res 23:1260–1267.Google Scholar
  4. Calabresi P, Welch AD (1962): Chemotherapy of neoplastic diseases. Annu Rev Med 13:147–202.CrossRefGoogle Scholar
  5. Calabresi P, Cardoso SS, Finch SC, Kligerman MM, von Essen CF, Chu MY, Welch AD (1961): Initial clinical studies with 5-iodo-2′-deoxyuridine. Cancer Res 21:550–559.Google Scholar
  6. Centifanto-Fitzgerald Y, Kaufman HE (1981): Herpes simplex virus strain specificity and ocular disease. In Herpetische Augenerkrankungen, Sundmacher R, ed. Munich: JF Bergmann Verlag, pp 19-24.Google Scholar
  7. Centifanto-Fitzgerald YM, Yamaguchi T, Kaufman HE, Tognon M, Roizman B (1982a): Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA. J Exp Med 155:475–489.CrossRefGoogle Scholar
  8. Centifanto-Fitzgerald YM, Varnell ED, Kaufman HE (1982b): Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains. Infect Immun 35:1125–1132.Google Scholar
  9. Centifanto-Fitzgerald YM, Fenger T, Kaufman HE (1982c): Virus proteins in herpetic keratitis. Exp Eye Res 35:425–441.CrossRefGoogle Scholar
  10. Delamore IW, Prusoff WH (1962): Effect of 5-iodo-2′-deoxyuridine on the biosynthesis of phosphorylated derivatives of thymidine. Biochem Pharmacol 11:101–112.CrossRefGoogle Scholar
  11. Dickinson L, Thompson MJ (1957): The antiviral action of threo-β-phenylserine. Br J Pharmacol 12:66–73.Google Scholar
  12. Draize JN, Woodard G, Cavery HO (1944): Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377–390.Google Scholar
  13. Easterbrook KB, Davern CI (1963): The effects of 5-bromodeoxyuridine on the multiplication of vaccinia virus. Virology 19:509–520.CrossRefGoogle Scholar
  14. Elion GB, Furman PA, Fyfe JA, De Miranda P, Beauchamp L, Schaeffer HJ (1977): Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74:5716–5720.CrossRefGoogle Scholar
  15. Hart DRL, Brightman VJF, Readshaw GG, Porter GTJ, Tully MJ (1965): Treatment of human herpes simplex keratitis with idoxuridine. Arch Ophthalmol 73:623–634.CrossRefGoogle Scholar
  16. Herrmann EC Jr (1961): Plaque inhibition test for detection of specific inhibitors of DNA containing viruses. Proc Soc Exp Biol Med 107:142–145.CrossRefGoogle Scholar
  17. Horsfall FL Jr, Tamm I (1957): Chemotherapy of viral and rickettsial diseases. Annu Rev Microbiol 11:339–370.CrossRefGoogle Scholar
  18. Jepson CN (1964): Treatment of herpes simplex of the cornea with IDU. Am J Ophthalmol 57:213–217.Google Scholar
  19. Kaufman HE (1962): Clinical cure of herpes simplex keratitis by 5-iodo-2′-deoxyuridine. Proc Soc Exp Biol Med 109:251–252.CrossRefGoogle Scholar
  20. Kaufman HE (1963a): Treatment of herpes simplex and vaccinia keratitis by 5-iodo-and 5-bromo-2′-deoxyuridine. Perspect Virol 111:90–107.Google Scholar
  21. Kaufman HE (1963b): Treatment of deep herpetic keratitis with IDU and corticosteroids. EENT Dig 25:37–40.Google Scholar
  22. Kaufman HE (1964): Epithelial erosion syndrome: Metaherpetic keratitis. Am J Ophthalmol 57:983–987.Google Scholar
  23. Kaufman HE (1965): In vivo studies with antiviral agents. Ann NY Acad Sci 130:168–180.CrossRefGoogle Scholar
  24. Kaufman HE (1978): Herpetic keratitis. Invest Ophthalmol Vis Sci 17:941–957.Google Scholar
  25. Kaufman HE, Heidelberger C (1964): Therapeutic antiviral action of 5-trifluoromethyl-2′-deoxyuridine. Science 145:585–586.CrossRefGoogle Scholar
  26. Kaufman HE, Maloney ED (1962): IDU and hydrocortisone in experimental herpes simplex keratitis. Arch Ophthalmol 68:396–398.CrossRefGoogle Scholar
  27. Kaufman HE, Nesburn AB, Maloney ED (1962a): IDU therapy of herpes simplex. Arch Ophthalmol 67:583–591.CrossRefGoogle Scholar
  28. Kaufman HE, Martola E-L, Dohlman CH (1962b): The use of 5-iodo-2′-deoxyuridine (IDU) in the treatment of herpes simplex keratitis. Arch Ophthalmol 68:235–239.CrossRefGoogle Scholar
  29. Kaufman HE, Maloney ED, Nesburn AB (1962c): Comparison of specific antiviral agents in herpes simplex keratitis. Invest Ophthalmol 1:686–692.Google Scholar
  30. Kaufman HE, Martola E-L, Dohlman CH (1963): Herpes simplex treatment with IDU and corticosteroids. Arch Ophthalmol 69:468–472.CrossRefGoogle Scholar
  31. Kaufman HE, Varnell ED, Centifanto-Fitzgerald YM, De Clercq E, Kissling GE (1983): Oral antiviral drugs in experimental herpes simplex keratitis. Antimicrob Agents Chemother 24:888–891.CrossRefGoogle Scholar
  32. Kaufman HE, Varnell ED, Cheng YC, Bobek M, Thompson HW, Dutschman GE (1991): Suppression of ocular herpes recurrences by a thymidine kinase inhibitor in squirrel monkeys. Antiviral Res 16:227–232.CrossRefGoogle Scholar
  33. Laibson PR, Leopold IH (1964): An evaluation of double blind IDU therapy in 100 cases of herpetic keratitis. Trans Am Acad Ophthalmol 68:22.Google Scholar
  34. Mathews REF, Smith JD (1955): The chemotherapy of viruses. Adv Virus Res 3:49–148.CrossRefGoogle Scholar
  35. Öberg B, Alenius S, Eriksson, B, Helgstrand E, Lundberg C, Lundström J (1982): Preclinical evaluation of the herpesvirus inhibitor foscarnet sodium. In Herpesvirus: Clinical Pharmacological, and Basic Aspects, Shiota H, Cheng Y-C, Prusoff WH, eds. Amsterdam: Excerpta Medica, pp 175–178.Google Scholar
  36. Paterson A, Fox AD, Davies G, Maguire C, Sellers PWH, Wright P, Rice NSC, Cobb B, Jones BR (1963): Controlled studies of IDU in the treatment of herpetic keratitis. Trans Ophthalmol Soc UK 83:583.Google Scholar
  37. Pons MW, Preston WS (1961): The in vivo inhibition by β-phenylserine of rabies, myxoma and vaccinia viruses. Virology 15:164–172.CrossRefGoogle Scholar
  38. Prusoff WH (1959): Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta 32:295–296.CrossRefGoogle Scholar
  39. Rasmussen AF Jr, Clark PF, Smith SC, Elvehjem CA (1951): Effect of 6-methyltryptophan on Lansing poliomyelitis in mice. Bacteriol Proc pp. 93-94.Google Scholar
  40. Sanitato JJ, Asbell PA, Varnell ED, Kissling G, Kaufman HE (1984): Acyclovir in the treatment of herpetic stromal disease. Am J Ophthalmol 98:537–547.Google Scholar
  41. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P (1978): 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group. Nature (London) 272:583–585.CrossRefGoogle Scholar
  42. Scholtissek C, Rott R (1961): Influence of p-fluorophenylalanine on the production of viral ribonucleic acid and on the utilization of viral protein during multiplication of fowl plague virus. Nature (London) 191:1023–1024.CrossRefGoogle Scholar
  43. Sery TW, Furgiuele FP (1961): The inactivation of herpes simplex virus by chemical agents. Am J Ophthalmol 51:42–57.Google Scholar
  44. Smeraglia R, Hochadel J, Varnell ED, Kaufman HE, Centifanto-Fitzgerald YM (1982): The role of herpes simplex virus secreted glycoproteins in herpetic keratitis. Exp Eye Res 35:443–459.CrossRefGoogle Scholar
  45. Wander AH, Centifanto YM, Kaufman HE (1980): Strain specificity of clinical isolates of herpes simplex virus. Arch Ophthalmol 98:1458–1461.CrossRefGoogle Scholar
  46. Welch AD (1961): Some metabolic approaches to cancer chemotherapy. Cancer Res 21:1475–1490.Google Scholar
  47. Wellings PC, Awdry PN, Bors FH, Jones BR, Brown DC, Kaufman HE (1972): Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am J Ophthalmol 73:932–942.Google Scholar
  48. Zimmermann T, Schafer W (1960): Effect of p-fluorophenylalanine on fowl plague virus multiplication. Virology 11:676–698.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Herbert E. Kaufman

There are no affiliations available

Personalised recommendations